Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cytisinicline, a plant-based alkaloid for smoking cessation and nicotine addiction. Cytisinicline interacts with nicotine receptors in the brain, reducing the severity of nicotine withdrawal symptoms. The company generates revenue through the sale and distribution of cytisinicline in Canada, the United States, and the United Kingdom. Achieve Life Sciences, Inc. holds license agreements with Sopharma AD and University of Bristol, enabling them to leverage their proprietary technology for commercialization and further product development.

Products

• Cytisinicline for smoking cessation and nicotine addiction